Rheumatoid

Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis

- Multinational Phase III Study Meets Primary Endpoint inRheumatoid Arthritis Patients Who Failed to Respond to Anti-tumorNecrosis Factor Treatments - NUTLEY, N.J., July 10, 2007 /PRNewswire/ -- Roche todayannounced that results from the Actemra Radiate (RheumAtoiDArthritIs Study in Anti-TNF FailurEs) trial successfully met itsprimary endpoint in patients with moderate to severe rheumatoi...

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA PatientsReported Job Loss When Treated With HUMIRA Combination TherapyCompared to Methotrexate Alone BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Rheumatoid arthritis (RA) is one of the most common causes ofdisability in the Western world. New data released today show thatrheumatoid arthritis (RA) patients treated with Abbott...

GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)

New Data to be Presented at the European League Against Rheumatism(EULAR) Congress Demonstrates the Potential Benefit of ofatumumabin Patients With Rheumatoid Arthritis LONDON, England; PHILADELPHIA, Pennsylvania and COPENHAGEN,Denmark, June 15, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline(GSK) and Genmab A/S (CSE: GEN) announced today positive primaryefficacy data (evaluated at 24 Week...

Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care

NUTLEY, N.J., June 15, 2007 /PRNewswire/ -- Results of theOption (TOcilizumab Pivotal Trial in Methotrexate InadequaterespONders) trial, the first multinational Phase III study outsideof Japan, showed that patients treated with Actemra (either 4mg/kgor 8mg/kg) plus methotrexate achieved a significant and clinicallyimportant improvement in the signs and symptoms of moderate tosevere rheum...

Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid Arthritis Study

Golimumab Demonstrated Sustained Improvement in Signs andSymptoms Of Moderate to Severe Rheumatoid Arthritis With One-Thirdof Patients Achieving Disease Remission at One-YearMark BARCELONA, Spain, 14 June 2007 – One-year data show nearly75 percent of patients with moderate to severe rheumatoid arthritis(RA) receiving golimumab (CNTO 148) and methotrexate (MTX)experienced a...

Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis

New Data Presented at EULAR Confirms Efficacy with Either EveryTwo Weeksn or Monthly Dosing BARCELONA, Spain, 14 June 2007 - 7:00 am CET - New pivotal data(RAPID 1 and RAPID 2) presented at the Annual European Congress ofRheumatology (EULAR) show that Cimzia (certolizumab pegol), thefirst PEGylated, Fc-free anti-TNF, combined with methotrexatetherapy has a rapid and significant eff...

Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment

NEW YORK, June 13, 2007--Three new drugs forrheumatoid arthritis (RA) have ushered in a new era of treatmentfor this difficult and debilitating condition. The findings arereported in a New Drug Class study published early Online and in anupcoming edition of The Lancet. RA is the most common of all chronicinflammatory joint diseases, affecting 0&middo...

Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR

THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Jun13, 2007 - Amgen (NASDAQ:AMGN) and Wyeth Pharmaceuticals, adivision of Wyeth (NYSE:WYE), today announced the presentation ofadditional data that showed that the safety profile of Enbrel(R)(etanercept) was maintained with long-term use in patients withmoderate-to-severe juvenile rheumatoid arthritis (JRA) whocompleted up to e...

New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis

Second Multinational Phase III Study Provides Further Evidence ofthe Significant Role of IL-6 Receptor Inhibition in the Treatmentof Rheumatoid Arthritis BASEL, Switzerland, June 6, 2007-Roche announced today thatToward (1), the second multinational phase III Actemra(tocilizumab) study, successfully reached its primary endpoint andshowed that a greater proportion of patients treated with...

New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR

COPENHAGEN, Denmark; April 25, 2007 - Genmab A/S (CSE: GEN)announced today that the results of a Phase II study withofatumumab (HuMax-CD20™) in patients with rheumatoidarthritis (RA) have been accepted for oral presentation at the 2007Annual European Congress of Rheumatology (EULAR). The oralpresentation, which will include new results from the double-blind,placebo controlled Phase...

Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma

SOUTH SAN FRANCISCO, Calif., April 11, 2007/PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. todayprovided a clinical update on R788, which is currently in ongoingPhase 2 clinical trials in immune thrombocytopenic purpura (ITP),rheumatoid arthritis (RA) and lymphoma patients. R788 is a novel,oral syk kinase inhibitor that blocks the activation of mast cells,macrophages and B-cells th...